An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry.
Len Woodward, Sally Johnson, Johan Vande Walle...
https://pubmed.ncbi.nlm.nih.gov/27871301/Actively Recruiting
Led by Alexion Pharmaceuticals, Inc. · Updated on 2025-09-16
3000
Participants Needed
141
Research Sites
N/A
Total Duration
This research aims to collect long-term safety and disease progression data on patients diagnosed with atypical hemolytic-uremic syndrome aHUS, including those treated or untreated with the drugs eculizumab or ravulizumab. The study is observational and involves multiple centers and countries, focusing on real-world information after these treatments have been marketed. Participants include patients of any age diagnosed with aHUS, regardless of whether they have identified complement genetic variants or antibodies. The study gathers data without administering new treatments, monitoring patients who may or may not have received eculizumab or ravulizumab. The registry collects information over extended periods to understand safety events and disease course. During the study, researchers track safety-related events over 10 years and the timing of these events within 5 years. Data collection involves reviewing patient health status and disease progression without altering their usual care. The study relies on informed consent and may include minors with appropriate assent. Participation duration varies, with continuous observation to gather comprehensive post-marketing safety data.
CONDITIONS
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
A
Alexion Pharmaceuticals, Inc. (Sponsor)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alexion Pharmaceuticals, Inc.
Lead Sponsor
Syneos Health
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants are observed to collect information on disease progression and post-marketing safety data.
Periodic visits as determined by the study protocol
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Len Woodward, Sally Johnson, Johan Vande Walle...
https://pubmed.ncbi.nlm.nih.gov/27871301/Gianluigi Ardissino, Ilaria Possenti, Francesca Tel...
https://pubmed.ncbi.nlm.nih.gov/24360866/Anja Gaeckler, Imad Al-Dakkak, Nuria Saval...
https://pubmed.ncbi.nlm.nih.gov/40875209/Christoph Licht, Gianluigi Ardissino, Gema Ariceta...
https://pubmed.ncbi.nlm.nih.gov/26654630/Mirco Belingheri, Ilaria Possenti, Francesca Tel...
https://pubmed.ncbi.nlm.nih.gov/24843058/Jean-Michel Halimi, Imad Al-Dakkak, Katerina Anokhina...
https://pubmed.ncbi.nlm.nih.gov/36152218/Alexion Pharmaceuticals, Inc.
Lead Sponsor
Syneos Health
Collaborating Sponsor